First Feline Immunodeficiency Virus Vaccine Ever to Be Approved for Commercial Use
Approved by the United States Department of Agriculture (USDA) — the first vaccine against lentiviruses to be considered of practical value by an official regulatory body worldwide.
An International Vaccine
Different global strains of FIV may change or mutate in the body. This vaccine is a dual-subtype, composed of two different strains from two different subgroups of the Virus, one from North America, one from Asia to provide cross-protection against other strains.
Backed by Research Conducted at Two Leading Veterinary Universities
The vaccine is the result of a 10 year collaboration and is being commercialized under license agreements with the Regents of the University of California and the University of Florida Research Foundation, assignees of the patents of Dr. Niels Pedersen of the University of California/Davis and Dr. Janet Yamamoto of the University of Florida as discoverers of the virus and Dr. Yamamoto’s patent for the vaccine technology.
Initial 3 Dose Series; Annual Booster; Minimum One Year Duration of Immunity Established By Challenge
Based on a heterologous challenge, the vaccine protected 84% of the vaccinates against infection while 90% of the controls became persistently viremic. The vaccine can be administered to kittens as young as eight weeks old.
